Sponsors (8)
The bill strengthens visibility, coordination, and preparedness for essential medicine supply chains—improving access for patients, planning for hospitals, and national-security oversight—at the cost of new reporting, compliance and administrative burdens, taxpayer-funded implementation, and risks to proprietary or sensitive supply‑chain information.
Patients with chronic conditions and other medicine-dependent people are more likely to retain access to critical drugs because the bill creates an essential medicines list, a federal inventory of vulnerabilities, and predictive analytics to anticipate and mitigate shortages.
Hospitals and health systems get clearer, actionable information (priority lists, domestic manufacturing data, and analytics) to improve preparedness, procurement planning, and contingency sourcing.
Federal preparedness and national security readiness improve because the bill identifies CBRN- and defense-relevant drugs, increases visibility into foreign reliance (enabling DPA or other responses), and gives DOD better oversight of defense medical supply links to foreign sources.
Taxpayers and the federal budget will face new costs to maintain, update, publish inventories and reports, run analytics and mapping, and otherwise fund implementation across agencies.
HHS, DoD, and other agencies will incur substantial administrative burdens (reporting, interagency coordination, biannual DOD reports, cybersecurity compliance), which can divert staff and resources from other programs.
Public reporting or interagency sharing of supply‑chain data risks revealing sensitive commercial or security information that adversaries could exploit or that could be misused despite protections.
Based on analysis of 7 sections of legislative text.
Requires HHS to maintain an Essential Medicines List and to assess, map, and report pharmaceutical supply‑chain risks (including China sourcing) to Congress and agencies to reduce shortages and security risks.
Official title: Improve coordination of Federal efforts to identify and mitigate health and national security risks through maintaining a list of essential medicines, conducting a risk assessment of essential medicine supply chains, and creating a monitoring system to map essential medicine supply chains using data analytics.
Introduced May 15, 2025 by Gary C. Peters · Last progress May 15, 2025
Requires the Secretary of Health and Human Services to maintain an "Essential Medicines List" of critical drugs and active pharmaceutical ingredients (APIs), then assess, map, and monitor U.S. supply chains for those medicines to identify vulnerabilities that threaten public health or national security. The bill directs interagency coordination (including with Defense), public and classified reporting to Congress, regular updates and risk assessments, mapping and analytics of supply chains, and recurring DoD disclosures about drugs connected to manufacturing or inputs sourced from the People’s Republic of China.